Catalyst Pharmaceutical Partners (CPRX) 1.81 $CPRX
Global Opium (Opioid) Addiction Therapeutics Pipeline Review 2014
M2 - Mon Apr 28, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bcl2wq/opium_opioid) has announced the addition of the "Global Opium (Opioid) Addiction Therapeutics Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Opium (Opioid) Addiction and enlists all their major and minor projects Companies Involved in Therapeutics Development - BioDelivery Sciences International, Inc. - Nanotherapeutics, Inc. - Acura Pharmaceuticals, Inc. - IntelGenx Corp. - Catalyst Pharmaceutical Partners, Inc. - Camurus AB - Omeros Corporation - D&A Pharma SAS - Reckitt Benckiser Pharmaceutical, Inc. - Relmada Therapeutics, Inc. - Celtic Pharmaceutical Holdings L.P. - Foresee Pharmaceuticals, LLC Drug Profiles - (buprenorphine naloxone) - TA-CD - OMS-403 - buprenorphine hydrochloride - RBP-6300 - OMS-405 - MAL - (buprenorphine hydrochloride naloxone hydrochloride) - CPP-115 - OMS-527 - buprenorphine hydrochloride ER - Ibogaine Analog - Heroin Vaccine - FP-004 - INT-0027 - methadone IR - Synthetic Peptides to Activate DOR and MOR and Inhibit MRP-1 for Oncology and Morphine Addiction - Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction For more information visit http://www.researchandmarkets.com/research/bc...ium_opioid
Global Dyskinesia Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wks94f/dyskinesia) has announced the addition of the "Global Dyskinesia Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyskinesia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Dyskinesia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Dyskinesia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Involved in Therapeutics Development - XenoPort, Inc. - Novartis AG - BioMarin Pharmaceutical Inc. - Addex Therapeutics - Avanir Pharmaceuticals, Inc. - NeuroSearch A/S - Catalyst Pharmaceutical Partners, Inc. - Neurim Pharmaceuticals Ltd - Santhera Pharmaceuticals Holding AG - Upsher-Smith Laboratories, Inc. - Adamas Pharmaceuticals, Inc. - Targacept, Inc. - Heptares Therapeutics Ltd. - Amarantus Bioscience Holdings, Inc. - SciFluor Life Sciences, LLC - SK Biopharmaceuticals Co., Ltd. - Merz Pharmaceuticals GmbH - Neurolixis Inc. - Contera Pharma ApS Drug Profiles - amantadine hydrochloride - AQW-051 - dipraglurant - eltoprazine - fipamezole - (dextromethorphan hydrobromide quinidine sulfate) - JM-010 - Neu-120 - ordopidine - SKL-PD - befiradol - naluzotan - CPP-115 - Acamprosate Prodrug - Neu-240 - MRZ-8676 - RGFP-109 - TC-8831 - NLX-112 - IRL-790 - Movement Disorders Program - Drug to Inhibit Dyskinesia and Hyperkinetic Movement Disorders - Small Molecule Targeting mGluR5 - Small Molecule For Dyskinesia - Small Molecules To Antagonise Metabotropic Glutamate Receptor 5 (mGluR5) For Dyskinesia For more information visit http://www.researchandmarkets.com/research/wks94f/dyskinesia
Catalyst Announces Initiation of an Expanded Access Program to Provide Firdapse at No Cost to U.S. Patients with Lambert-Eaton Myasthenic Syndrome
Business Wire - Wed Apr 23, 7:03AM CDT
Catalyst Pharmaceutical Partners, Inc. announced today it has begun the process required to establish an expanded access program (EAP) to make available in the United States its investigational potassium channel inhibitor, Firdapse(TM) (amifampridine phosphate or 3,4-DAP phosphate), to patients diagnosed with Lambert-Eaton Myasthenic Syndrome (LEMS) through their neuromuscular disease specialists. The product, currently in Phase 3 development, will be provided at no cost until sometime after approval. Program enrollment will begin in the next few months, pending FDA review and approvals.
Prana Biotechnology Stock Hits New Low
ACCESSWIRE - Wed Apr 16, 9:47AM CDT
Prana Biotechnology (NASDAQ
RAN) share value has been tumbling over the last month, closing at $1.74 Apr. 15, down 15 cents from the previous day's close of $1.89.
Global Tourette Syndrome Therapeutic Pipeline Review 2014
M2 - Tue Apr 15, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/78vx5h/tourette_syndrome) has announced the addition of the "Tourette Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tourette Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tourette Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Tourette Syndrome - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tourette Syndrome and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tourette Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Tourette Syndrome pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Tourette Syndrome - Companies Involved in Therapeutics Development - AstraZeneca PLC - Neurocrine Biosciences, Inc. - NeuroSearch A/S - Catalyst Pharmaceutical Partners, Inc. - Auspex Pharmaceuticals, Inc. - Edison Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Psyadon Pharmaceuticals, Inc. Drug Profiles - aripiprazole - ecopipam hydrochloride - AZD-5213 - acetylcysteine - vigabatrin - valbenazine - seridopidine - vatiquinone - RP-5063 - SD-809 ER For more information visit http://www.researchandmarkets.com/research/78...e_syndrome
A Small-Cap Biotech Stock on the Verge of a Breakout
at The Street - Wed Apr 09, 1:58PM CDT
This small-cap biotech stock should be on your trading radar.
Catalyst Pharmaceutical Partners concludes public offering at USD2.21 per share
M2 - Wed Apr 09, 5:08AM CDT
Pharmaceutical company Catalyst Pharmaceutical Partners (NasdaqCM:CPRX) revealed on Tuesday the completion of its public offering at an offering price of USD2.21 per share.
Catalyst Pharmaceutical Partners, Inc. Announces Closing of Previously Announced Public Offering
GlobeNewswire - Tue Apr 08, 9:30AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today reported that it has closed its previously announced public offering of shares of its common stock. The Company sold 13,023,750 shares of its common stock in the offering, including 1,698,750 shares that were issued upon the exercise by the underwriters of their overallotment option. The offering price was $2.21 per share, and the net proceeds from the sale of the shares is expected to be $26.8 million. Piper Jaffray & Co. acted as the sole book-running manager for the offering, Roth Capital Partners acted as co-lead manager, and H.C. Wainwright & Co., LLC acted as co-manager with respect to the offering.
Catalyst Pharmaceutical Partners Inc. (CPRX) Jumps: Stock Up 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 7:51AM CDT
Catalyst Pharmaceutical Partners Inc. was a big mover last session, as its shares rose nearly 9% on the day.
3 Stocks Under $10 Making Big Moves
at The Street - Fri Apr 04, 7:43AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Catalyst Pharmaceutical Partners prices public offering at USD2.21 per share
M2 - Fri Apr 04, 6:13AM CDT
Pharmaceutical company Catalyst Pharmaceutical Partners (NasdaqCM:CPRX) reported on Thursday that it has priced its public offering of 11,325,000 shares of its common stock at USD2.21 per share.
Pandora Media March Active Listener Hours Up 14% in March; eBay Looking to Grow Annual Revenue to $21B by 2015
ACCESSWIRE - Thu Apr 03, 11:20PM CDT
Pandora Media, Inc. (NYSE: P) - For an in-depth report on Pandora Media, Inc. follow: www.BullTrends.com/stockquote/P
Catalyst Pharmaceutical Partners, Inc. Prices Public Offering of Common Stock
GlobeNewswire - Thu Apr 03, 8:00AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced the pricing of its previously announced underwritten public offering of 11,325,000 shares of its common stock at an offering price of $2.21 per share. In connection with the offering, Catalyst has also granted the underwriters a 30-day option to purchase up to an additional 1,698,750 shares of common stock to cover over-allotments, if any.
Catalyst Pharmaceutical Partners concludes patient enrollment in pivotal Phase 3 trial of Firdapse in Lambert-Eaton Myasthenic Syndrome patients
M2 - Wed Apr 02, 4:46AM CDT
Pharmaceutical company Catalyst Pharmaceutical Partners (NasdaqCM:CPRX) reported on Tuesday the completion of patient enrollment under its pivotal Phase 3 trial evaluating the safety and efficacy of Firdapse for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS), a neuromuscular and neurological disease.
Catalyst Announces Completion of Enrollment in Pivotal Phase 3 Trial of Firdapse(TM) in Patients With Lambert-Eaton Myasthenic Syndrome
GlobeNewswire - Tue Apr 01, 8:25AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective, approved medicines to treat orphan neuromuscular and neurological diseases, announced today that it has reached the patient enrollment target for its pivotal Phase 3 trial evaluating the safety and efficacy of Firdapse(TM) for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS).
Catalyst Pharmaceutical Partners Expands Executive Leadership Team to Support the Commercialization of Firdapse(TM)
GlobeNewswire - Fri Mar 28, 7:03AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective, FDA-approved medicines targeting orphan neuromuscular and neurological diseases, today announced the appointment of Barrett S. McGrath as Chief Commercial Officer, a newly created position. McGrath will lead the formation of Catalyst's North America commercial strategy and organization. McGrath will report to Patrick McEnany, Chairman, President and Chief Executive Officer of Catalyst.
Good News for Catalyst Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 5:30PM CDT
The independent DMC has recommended the continuation of Catalyst Pharma's phase III study on Firdapse.
Catalyst Pharmaceutical Partners Announces Recommendation of Data Monitoring Committee to Continue Pivotal Phase 3 Clinical Trial for Firdapse(TM)
GlobeNewswire - Tue Mar 25, 7:17AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological diseases, announced today that, at a recently held meeting, the independent Data Monitoring Committee (DMC) overseeing the Company's ongoing pivotal Phase 3 clinical trial evaluating Firdapse(TM) for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) recommended that the trial be continued as planned based on the committee's review of safety and clinical data from the trial.
Pre-Market Analysis on Top Gainers -- Research on ZIOPHARM, Centrais Eletricas Brasileiras, Catalyst Pharma Partners and Sinovac Biotech
PR Newswire - Fri Mar 21, 4:18PM CDT
The US markets saw a positive sentiment on Thursday, March 20, 2014, with the NASDAQ Composite closing at 4,319.29, up 0.27%, the Dow Jones Industrial Average ending the session at 16,331.05, up 0.67% and the S&P 500 edging 0.60% higher to finish the trading session at 1,872.01. During the session, gains in the Information Technology, Financials, and Telecommunication Services sectors positively impacted the broader market. A number of stocks saw large movements, including ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Centrais Eletricas Brasileiras S.A. (NYSE: EBR), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) and Sinovac Biotech Ltd (NASDAQ: SVA). Free technical research on ZIOP, EBR, CPRX and SVA can be downloaded upon signing up at:
Catalyst Pharmaceutical Partners (CPRX) in Focus: Stock Moves 6.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 8:21AM CDT
Catalyst Pharmaceutical Partners Inc. (CPRX) was a big mover last session, as the company saw its shares rise by over 6% on the day.
Global Opium (Opioid) Addiction Therapeutics Pipeline Review 2014
M2 - Mon Apr 28, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bcl2wq/opium_opioid) has announced the addition of the "Global Opium (Opioid) Addiction Therapeutics Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Opium (Opioid) Addiction and enlists all their major and minor projects Companies Involved in Therapeutics Development - BioDelivery Sciences International, Inc. - Nanotherapeutics, Inc. - Acura Pharmaceuticals, Inc. - IntelGenx Corp. - Catalyst Pharmaceutical Partners, Inc. - Camurus AB - Omeros Corporation - D&A Pharma SAS - Reckitt Benckiser Pharmaceutical, Inc. - Relmada Therapeutics, Inc. - Celtic Pharmaceutical Holdings L.P. - Foresee Pharmaceuticals, LLC Drug Profiles - (buprenorphine naloxone) - TA-CD - OMS-403 - buprenorphine hydrochloride - RBP-6300 - OMS-405 - MAL - (buprenorphine hydrochloride naloxone hydrochloride) - CPP-115 - OMS-527 - buprenorphine hydrochloride ER - Ibogaine Analog - Heroin Vaccine - FP-004 - INT-0027 - methadone IR - Synthetic Peptides to Activate DOR and MOR and Inhibit MRP-1 for Oncology and Morphine Addiction - Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction For more information visit http://www.researchandmarkets.com/research/bc...ium_opioid
Global Dyskinesia Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wks94f/dyskinesia) has announced the addition of the "Global Dyskinesia Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyskinesia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Dyskinesia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Dyskinesia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Involved in Therapeutics Development - XenoPort, Inc. - Novartis AG - BioMarin Pharmaceutical Inc. - Addex Therapeutics - Avanir Pharmaceuticals, Inc. - NeuroSearch A/S - Catalyst Pharmaceutical Partners, Inc. - Neurim Pharmaceuticals Ltd - Santhera Pharmaceuticals Holding AG - Upsher-Smith Laboratories, Inc. - Adamas Pharmaceuticals, Inc. - Targacept, Inc. - Heptares Therapeutics Ltd. - Amarantus Bioscience Holdings, Inc. - SciFluor Life Sciences, LLC - SK Biopharmaceuticals Co., Ltd. - Merz Pharmaceuticals GmbH - Neurolixis Inc. - Contera Pharma ApS Drug Profiles - amantadine hydrochloride - AQW-051 - dipraglurant - eltoprazine - fipamezole - (dextromethorphan hydrobromide quinidine sulfate) - JM-010 - Neu-120 - ordopidine - SKL-PD - befiradol - naluzotan - CPP-115 - Acamprosate Prodrug - Neu-240 - MRZ-8676 - RGFP-109 - TC-8831 - NLX-112 - IRL-790 - Movement Disorders Program - Drug to Inhibit Dyskinesia and Hyperkinetic Movement Disorders - Small Molecule Targeting mGluR5 - Small Molecule For Dyskinesia - Small Molecules To Antagonise Metabotropic Glutamate Receptor 5 (mGluR5) For Dyskinesia For more information visit http://www.researchandmarkets.com/research/wks94f/dyskinesia
Catalyst Announces Initiation of an Expanded Access Program to Provide Firdapse at No Cost to U.S. Patients with Lambert-Eaton Myasthenic Syndrome
Business Wire - Wed Apr 23, 7:03AM CDT
Catalyst Pharmaceutical Partners, Inc. announced today it has begun the process required to establish an expanded access program (EAP) to make available in the United States its investigational potassium channel inhibitor, Firdapse(TM) (amifampridine phosphate or 3,4-DAP phosphate), to patients diagnosed with Lambert-Eaton Myasthenic Syndrome (LEMS) through their neuromuscular disease specialists. The product, currently in Phase 3 development, will be provided at no cost until sometime after approval. Program enrollment will begin in the next few months, pending FDA review and approvals.
Prana Biotechnology Stock Hits New Low
ACCESSWIRE - Wed Apr 16, 9:47AM CDT
Prana Biotechnology (NASDAQ
RAN) share value has been tumbling over the last month, closing at $1.74 Apr. 15, down 15 cents from the previous day's close of $1.89. Global Tourette Syndrome Therapeutic Pipeline Review 2014
M2 - Tue Apr 15, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/78vx5h/tourette_syndrome) has announced the addition of the "Tourette Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tourette Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tourette Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Tourette Syndrome - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tourette Syndrome and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tourette Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Tourette Syndrome pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Tourette Syndrome - Companies Involved in Therapeutics Development - AstraZeneca PLC - Neurocrine Biosciences, Inc. - NeuroSearch A/S - Catalyst Pharmaceutical Partners, Inc. - Auspex Pharmaceuticals, Inc. - Edison Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Psyadon Pharmaceuticals, Inc. Drug Profiles - aripiprazole - ecopipam hydrochloride - AZD-5213 - acetylcysteine - vigabatrin - valbenazine - seridopidine - vatiquinone - RP-5063 - SD-809 ER For more information visit http://www.researchandmarkets.com/research/78...e_syndrome
A Small-Cap Biotech Stock on the Verge of a Breakout
at The Street - Wed Apr 09, 1:58PM CDT
This small-cap biotech stock should be on your trading radar.
Catalyst Pharmaceutical Partners concludes public offering at USD2.21 per share
M2 - Wed Apr 09, 5:08AM CDT
Pharmaceutical company Catalyst Pharmaceutical Partners (NasdaqCM:CPRX) revealed on Tuesday the completion of its public offering at an offering price of USD2.21 per share.
Catalyst Pharmaceutical Partners, Inc. Announces Closing of Previously Announced Public Offering
GlobeNewswire - Tue Apr 08, 9:30AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today reported that it has closed its previously announced public offering of shares of its common stock. The Company sold 13,023,750 shares of its common stock in the offering, including 1,698,750 shares that were issued upon the exercise by the underwriters of their overallotment option. The offering price was $2.21 per share, and the net proceeds from the sale of the shares is expected to be $26.8 million. Piper Jaffray & Co. acted as the sole book-running manager for the offering, Roth Capital Partners acted as co-lead manager, and H.C. Wainwright & Co., LLC acted as co-manager with respect to the offering.
Catalyst Pharmaceutical Partners Inc. (CPRX) Jumps: Stock Up 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 7:51AM CDT
Catalyst Pharmaceutical Partners Inc. was a big mover last session, as its shares rose nearly 9% on the day.
3 Stocks Under $10 Making Big Moves
at The Street - Fri Apr 04, 7:43AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Catalyst Pharmaceutical Partners prices public offering at USD2.21 per share
M2 - Fri Apr 04, 6:13AM CDT
Pharmaceutical company Catalyst Pharmaceutical Partners (NasdaqCM:CPRX) reported on Thursday that it has priced its public offering of 11,325,000 shares of its common stock at USD2.21 per share.
Pandora Media March Active Listener Hours Up 14% in March; eBay Looking to Grow Annual Revenue to $21B by 2015
ACCESSWIRE - Thu Apr 03, 11:20PM CDT
Pandora Media, Inc. (NYSE: P) - For an in-depth report on Pandora Media, Inc. follow: www.BullTrends.com/stockquote/P
Catalyst Pharmaceutical Partners, Inc. Prices Public Offering of Common Stock
GlobeNewswire - Thu Apr 03, 8:00AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced the pricing of its previously announced underwritten public offering of 11,325,000 shares of its common stock at an offering price of $2.21 per share. In connection with the offering, Catalyst has also granted the underwriters a 30-day option to purchase up to an additional 1,698,750 shares of common stock to cover over-allotments, if any.
Catalyst Pharmaceutical Partners concludes patient enrollment in pivotal Phase 3 trial of Firdapse in Lambert-Eaton Myasthenic Syndrome patients
M2 - Wed Apr 02, 4:46AM CDT
Pharmaceutical company Catalyst Pharmaceutical Partners (NasdaqCM:CPRX) reported on Tuesday the completion of patient enrollment under its pivotal Phase 3 trial evaluating the safety and efficacy of Firdapse for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS), a neuromuscular and neurological disease.
Catalyst Announces Completion of Enrollment in Pivotal Phase 3 Trial of Firdapse(TM) in Patients With Lambert-Eaton Myasthenic Syndrome
GlobeNewswire - Tue Apr 01, 8:25AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective, approved medicines to treat orphan neuromuscular and neurological diseases, announced today that it has reached the patient enrollment target for its pivotal Phase 3 trial evaluating the safety and efficacy of Firdapse(TM) for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS).
Catalyst Pharmaceutical Partners Expands Executive Leadership Team to Support the Commercialization of Firdapse(TM)
GlobeNewswire - Fri Mar 28, 7:03AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective, FDA-approved medicines targeting orphan neuromuscular and neurological diseases, today announced the appointment of Barrett S. McGrath as Chief Commercial Officer, a newly created position. McGrath will lead the formation of Catalyst's North America commercial strategy and organization. McGrath will report to Patrick McEnany, Chairman, President and Chief Executive Officer of Catalyst.
Good News for Catalyst Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 5:30PM CDT
The independent DMC has recommended the continuation of Catalyst Pharma's phase III study on Firdapse.
Catalyst Pharmaceutical Partners Announces Recommendation of Data Monitoring Committee to Continue Pivotal Phase 3 Clinical Trial for Firdapse(TM)
GlobeNewswire - Tue Mar 25, 7:17AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological diseases, announced today that, at a recently held meeting, the independent Data Monitoring Committee (DMC) overseeing the Company's ongoing pivotal Phase 3 clinical trial evaluating Firdapse(TM) for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) recommended that the trial be continued as planned based on the committee's review of safety and clinical data from the trial.
Pre-Market Analysis on Top Gainers -- Research on ZIOPHARM, Centrais Eletricas Brasileiras, Catalyst Pharma Partners and Sinovac Biotech
PR Newswire - Fri Mar 21, 4:18PM CDT
The US markets saw a positive sentiment on Thursday, March 20, 2014, with the NASDAQ Composite closing at 4,319.29, up 0.27%, the Dow Jones Industrial Average ending the session at 16,331.05, up 0.67% and the S&P 500 edging 0.60% higher to finish the trading session at 1,872.01. During the session, gains in the Information Technology, Financials, and Telecommunication Services sectors positively impacted the broader market. A number of stocks saw large movements, including ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Centrais Eletricas Brasileiras S.A. (NYSE: EBR), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) and Sinovac Biotech Ltd (NASDAQ: SVA). Free technical research on ZIOP, EBR, CPRX and SVA can be downloaded upon signing up at:
Catalyst Pharmaceutical Partners (CPRX) in Focus: Stock Moves 6.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 8:21AM CDT
Catalyst Pharmaceutical Partners Inc. (CPRX) was a big mover last session, as the company saw its shares rise by over 6% on the day.
